It already tests most of the US and European blood supplies and has for a couple of years. It was too good to let FDA approval get in the way of its use. But according to the rules, the company wasn't allowed to make a profit selling the technology until it was approved by the FDA. The FDA literally dragged their heels until they were forced to make a decision due to a mandatory deadline on the last day of February. The government stood to save money by not approving it since they are one of its biggest users, and not approving it allowed them to use it on the cheap because the company was not allowed to make a profit on the government's widespread usage of it.
The same technology also currently tests for Hep-C. Additional viral RNA/DNA profiles are being added to the library that the technology can screen for.